Leveraging Innovation To Deliver Precision Medicines

Pipeline

PD-L1

Strong scientific and clinical rationale for novel small molecule PD-L1 inhibitor

Rationale

  • PD1/PD-L1 pathway is a critical immune checkpoint in T-cell proliferation
  • In the tumor microenvironment, PD-1 and PD-L1 perform a vital role in tumor progression and survival by protecting tumors from immune surveillance
  • Targeting PD-1/PD-L1 pathway could reactivate cytotoxic T cells to work against cancer cells
  • Anti-PD1/PD-L1 mAbs increase overall survival compared to standard of care in different tumors
  • Autoimmune reactions caused by sustained activation of immune cells by mAb can potentially be overcome with a small molecule
  • Low patient compliance and high cost of mAb therapies can also be overcome with a small molecule

Opportunity

  • Potential use after initial mAb treatment as a lower-cost maintenance therapy
  • Flexibility to combine with other I/O and targeted therapies
  • Combination in non-oncology indications, e.g HBV where small molecule PD-1 oral modality is preferred over IV mAbs

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.